Xona already holds the exclusive license to manufacture its neuronal research devices in the US, and this new European patent adds to its exclusivity in Europe, specifically the United Kingdom, Ireland, Switzerland, France, Spain and Germany.
The patents are assigned to the University of California and licensed exclusively to Xona.
Dr. Anne Taylor, Assistant Professor at the University of North Carolina at Chapel Hill, invented the neuron device while working as a graduate student in the laboratory of Dr. Noo Li Jeon at the University of California, Irvine in 2003. Dr. Carl Cotman, Professor of Neuroscience at the University of California, Irvine, helped guide Dr. Taylor's research.
Dr. Taylor, Dr. Jeon and Dr. Cotman are all credited as co-inventors.
Xona Microfluidics is focused on manufacturing and distributing microfluidic devices to neuroscientists and laboratories worldwide. The company has offices in Temecula, California and Research Triangle Park in Durham, North Carolina.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA